KUALA LUMPUR: Hong Seng Consolidated Bhd (HSC) inked a laboratory services agreement with RZAC Immunesafe Sdn Bhd (RISB) and Aster Technologies Sdn Bhd (ATSB) for ImmuSAFE COVID+ Biochip laboratory testing.
The agreement was inked by Neogenix Laboratoire Sdn Bhd (NLSB), a 60 per cent owned subsidiary of HS Bio Sdn Bhd, a wholly-owned subsidiary of HSC.
NLSB is licenced to provide laboratory testing for the ImmuSAFE COVID+ Biochip to RISB and ATSB under the terms of the agreement.
In contrast, ATSB is licenced to provide logistic services to collect and deliver test samples to RISB.
RISB is the authorised distributor of the ImmuSAFE COVID+ Biochip and has been working with the government through Malaysia Automotive, Robotics and IoT Institute (MARii) to commercialise the biochip.
ATSB is a company involved in the retail of ImmuSAFE COVID+ Biochip and the provision of medical logistic services.
NLSB managing director Dr Kuan Chee Sian said the company is excited for the opportunity to be involved in the next stage of the battle against Covid-19.
"We will be able to utilise our experience in the field of medical diagnostic and research to help curb the ongoing spread of the Covid-19 virus.
"NLSB recognises the importance of antibody testing to assist people in making informed clinical decisions about their health and help verify the effectiveness of vaccine protection," he said in a statement today.